Metropolis Healthcare achieves revenue growth of 40% in Q4FY21

08 Apr 2021

Metropolis Healthcare has achieved a revenue growth of 40% Year on Year (YoY) in Q4FY21 as compared to Q4FY20. Non-Covid Business revenue increased by 21% YoY in Q4FY21 as compared to Q4FY20. Inspite of conducting higher Covid Tests on QoQ basis, Covid Business revenue (RT-PCR Tests) stood at 14% of total revenue in Q4FY21 as compared to 19% in Q3FY21 due to reduction in Test prices by Government agencies.

The Company recorded highest ever monthly revenue in March 2021 on the back of strong growth in Non-covid business coupled with an uptick in covid business.

Metropolis Healthcare offers a comprehensive range of clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.

Related Metropolis Healthcare Ltd. Links:

Metropolis Health. Share Price

2484.45 49.55 (2.03%) Apr 16, 18:01
1 Year Price Chart
Company Name CMP
Apollo Hospital Ent. 3060.20
Aster DM Healthcare 146.55
Narayana Hrudayalay 401.50
Dr Lal Pathlabs 2917.80
Metropolis Health. 2484.45
View more..
Sensex vs Metropolis Health.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323